Biotech News

Candel Therapeutics Reports Third Quarter 2026 Financial Results and Recent Corporate Highlights

Candel Therapeutics (CADL)Candel TherapeuticsEarnings

The Company is in ongoing dialogue with the FDA regarding the submission of a Biologics License Application (BLA) for aglatimagene in prostate cancer. Due to timelines associated with certain assay refinement, the Company currently plans to submit this BLA in the middle of 2027 pending the result

Related news

Candel Therapeutics

Multimodal Cancer Immunotherapy Candel Therapeutics develops locally administered viral immunotherapies intended to induce immunogenic tumor-cell death and a systemic antitumor immune response. Aglatimagene Besadenovec Aglatimagene is an off-the-shelf, replication-defective adenovirus that delivers the HSV-thymidine-kinase gene into...

Recent company news

Stock data

Close
5.13 USD
Market cap
616.94M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States